|Bid||3.4800 x 1800|
|Ask||3.5400 x 1000|
|Day's range||3.1100 - 3.6850|
|52-week range||1.0100 - 4.0700|
|Beta (5Y monthly)||1.99|
|PE ratio (TTM)||N/A|
|Earnings date||06 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||7.25|
Investors are thrilled with the results from a late-stage clinical study of the company's only pipeline drug candidate.
Many investors have been worried about the Nasdaq Composite (NASDAQINDEX: ^IXIC) lately. The index has taken a leadership role during 2020's huge rebound from the coronavirus bear market, but its steep decline in early September made some believe that the best of times for the Nasdaq were now behind it. The Nasdaq gained more than 1% in early trading Tuesday, and helping to lead that charge was new enthusiasm about drugmaker Marinus Pharmaceuticals (NASDAQ: MRNS).
Marinus Pharmaceuticals (MRNS) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.